144 related articles for article (PubMed ID: 26983288)
1. Are We There Yet?
Tsai A
Diabetes Forecast; 2016; 69(1):52-7. PubMed ID: 26983288
[No Abstract] [Full Text] [Related]
2. Jentadueto XR for type 2 diabetes.
Med Lett Drugs Ther; 2016 Aug; 58(1500):98-100. PubMed ID: 27466749
[No Abstract] [Full Text] [Related]
3. Approaches to treatment 1: How is type 2 diabetes actually treated?
Bloomgarden ZT
J Diabetes; 2015 Nov; 7(6):747-8. PubMed ID: 26211568
[No Abstract] [Full Text] [Related]
4. Diabetes: Time for reconciliation between cardiologists and diabetologists.
Scheen AJ
Nat Rev Cardiol; 2016 Sep; 13(9):509-10. PubMed ID: 27411401
[No Abstract] [Full Text] [Related]
5. Insulin degludec/liraglutide (Xultophy 100/3.6) for type 2 diabetes.
Med Lett Drugs Ther; 2017 Sep; 59(1529):147-149. PubMed ID: 28880845
[No Abstract] [Full Text] [Related]
6. Canagliflozin, alogliptin benzoate, and ospemifene.
Hussar DA; Frimpong JO
J Am Pharm Assoc (2003); 2013; 53(4):442-7. PubMed ID: 23892821
[No Abstract] [Full Text] [Related]
7. Insulin Innovations.
Curry A
Diabetes Forecast; 2015; 68(4):38-43. PubMed ID: 26374923
[No Abstract] [Full Text] [Related]
8. Type 2 Diabetes: Progress Made but Still a Long Road to Travel to Reduce Disease Burden.
Terra SG; Vincent J
Clin Pharmacol Ther; 2015 Aug; 98(2):108-11. PubMed ID: 26013760
[No Abstract] [Full Text] [Related]
9. American Diabetes Association Standards of Medical Care in Diabetes 2017.
Marathe PH; Gao HX; Close KL
J Diabetes; 2017 Apr; 9(4):320-324. PubMed ID: 28070960
[No Abstract] [Full Text] [Related]
10. Novo Nordisk incretin and Cardiovascular Summit, Durban, June 2013.
Wagenaar P
Cardiovasc J Afr; 2013 Sep; 24(8):340. PubMed ID: 24240386
[No Abstract] [Full Text] [Related]
11. Tenacious D. why beta cells are no match for the relentless persistence of type 2 diabetes.
Curry A
Diabetes Forecast; 2015; 68(5):38-41. PubMed ID: 26491753
[No Abstract] [Full Text] [Related]
12. SGLT2 Inhibitors and Ketoacidosis: Cause for Concern?
Abate N; Chandalia M
Metab Syndr Relat Disord; 2016 Feb; 14(1):1-2. PubMed ID: 26554527
[No Abstract] [Full Text] [Related]
13. Fiasp--another insulin aspart formulation for diabetes.
Med Lett Drugs Ther; 2018 Jan; 60(1537):6-7. PubMed ID: 29294464
[No Abstract] [Full Text] [Related]
14. Pharmacologic treatment of type 2 diabetes mellitus: realities and perspectives.
Abdallah MP; Hirbli K
J Med Liban; 1999; 47(4):233-7. PubMed ID: 10641451
[No Abstract] [Full Text] [Related]
15. Glucose products.
Berg EG
Diabetes Forecast; 2014 Jan; 67(1):76-7. PubMed ID: 25868301
[No Abstract] [Full Text] [Related]
16. American Diabetes Association 78th Scientific Sessions.
Kurian MJ; Carracher AM; Close KL
J Diabetes; 2018 Nov; 10(11):816-819. PubMed ID: 30054971
[TBL] [Abstract][Full Text] [Related]
17. Iixisenatide. Wait for conclusive results on complications of diabetes.
Prescrire Int; 2014 Oct; 23(153):234-5. PubMed ID: 25964965
[TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic fatty liver disease and type 2 diabetes: Importance of glycemic control.
Bloomgarden Z
J Diabetes; 2017 Aug; 9(8):722-723. PubMed ID: 28513098
[No Abstract] [Full Text] [Related]
19. Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes.
Mannucci E; Monami M; Ceriello A; Rotella CM
Nutr Metab Cardiovasc Dis; 2017 Apr; 27(4):375-377. PubMed ID: 28242233
[No Abstract] [Full Text] [Related]
20. Cardiovascular Safety Trials for All New Diabetes Mellitus Drugs?
Low Wang CC; Everett BM; Burman KD; Wilson PWF
Circulation; 2019 Apr; 139(14):1741-1743. PubMed ID: 30933621
[No Abstract] [Full Text] [Related]
[Next] [New Search]
